NYU Langone Health and Dana-Farber Cancer Institute have launched a joint effort to bring a new cancer care decision tool to hospitals and clinics nationwide. The two renowned health systems announced a strategic partnership to co-develop the Solavia Decision Suite, an oncology support platform that aims to help physicians deliver more consistent, evidence-based treatment. The platform is now commercially available after first launching internally at NYU Langone in late June.
Combining Clinical Expertise and Technology
The collaboration draws on each organization’s strengths. NYU Langone brings its information technology infrastructure and platform development experience, while Dana-Farber contributes its clinical pathways expertise and decades of oncology research. Officials from both institutions said the goal is to give doctors better access to current guidelines and treatment options without leaving their electronic health record systems.
“Solavia represents an important opportunity to deploy the next generation of oncology decision support for clinicians and patients,” said Nader Mherabi, executive vice president, vice dean, and chief digital and information officer at NYU Langone. “By co-developing this platform with Dana-Farber, we are translating clinical expertise into a scalable strategic capability that can improve consistency in care and accelerate the adoption of the latest evidence in oncology practice.”
The platform embeds directly into existing EHR workflows, a design choice meant to reduce friction for busy clinicians. Rather than switching between separate applications, physicians can pull up the latest evidence, biomarker information, and therapeutic guidelines within their normal documentation environment. NYU Langone officials said testing the platform internally first helped them refine how it performs under real-world conditions before offering it to other organizations.
Related: Making Wellness Part of Your Journey: Using Natural Products for Sleep, Relaxation, or Energy
Standardizing Cancer Care Delivery
Oncology treatment varies significantly across providers and regions, even when patients have similar diagnoses. The organizations behind Solavia said they hope to narrow that gap by giving care teams a shared framework grounded in established research.
“Solavia is designed with clinicians in mind and patients at the center,” said David Jackman, M.D., medical director of clinical pathways and new business initiatives at Dana-Farber. “The platform is intended to support care teams with evidence-based, context-aware guidance that helps make cancer treatment more personalized, coordinated, and consistent.”
Both health systems expect the platform to strengthen care standardization and reduce unnecessary variation in how treatment decisions are made. The organizations plan to expand adoption beyond their own facilities, though a specific timeline for broader rollout was not detailed in the announcement. Officials said the platform will continue to evolve as new evidence emerges and more institutions provide feedback on its performance in diverse clinical settings.
